Home | Business News | Browse by Publication | P | PR Newswire

Prospect Therapeutics Inc.'s GCS-100 Has Focused on Developing Treatment for Three Blood-Borne Cancers.

Publication: PR Newswire
Publication Date: 22-JUN-09
Format: Online
Delivery: Immediate Online Access

Article Excerpt
WELLESLEY HILLS, Mass., June 22 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") announced today that Prospect Therapeutics has focused on developing GCS-100 for treatment of three blood-borne cancers: chronic lymphocytic leukemia ("CLL"), multiple myeloma ("MM") and diffuse large B cell lymphoma ("DLBCL"). In clinical studies, GCS-100 has demonstrated...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!



More articles from PR Newswire
Frost & Sullivan Selects Bone Solutions for Technology Leadership of t..., June 22, 2009
iStreet Solutions, LLC - an SAP Hosting Partner - Announces SAS70 Type..., June 22, 2009
St. Louis Rams Select State-of-the-Art System from AstroTurf(R) for Pr..., June 22, 2009
MUSCLEPHARM Products Hit Vitamin Shoppe Shelves With a Bang!, June 22, 2009
Automotive-grade Ceramic SMD Crystals from Fox Electronics Withstand H..., June 22, 2009

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.